8242:RENEW 1-Weight loss in people living with overweight/obesity following treatment-Cagrilintide
Research type
Research Study
Full title
Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity
IRAS ID
1012541
Contact name
Clinical Transparency Dept 2834
Contact email
Sponsor organisation
Novo Nordisk A/S
Eudract number
2024-519530-24
Research summary
People living with overweight or obesity may have increased risk of getting serious diseases such as type 2 diabetes, high blood pressure and heart diseases due to excess body weight. Lowering body weight lowers the risk of getting these diseases. Exercise and diet can help some people to lower their body weight. Other people need extra treatments to lose weight. Cagrilintide is a medicine that can help people lose weight. This study will look at the weight loss in participants who take cagrilintide compared to participants who take placebo which looks like the treatment being tested but does not have any active medicine in it. The study will also look at how safe cagrilintide is.
Throughout the study, they will follow diet and exercise plans.REC name
London - Westminster Research Ethics Committee
REC reference
25/LO/0506
Date of REC Opinion
3 Sep 2025
REC opinion
Further Information Favourable Opinion